share_log

AstraZeneca's ALXN1840 Shows Promising Action Against Copper Metabolism Disorder

AstraZeneca's ALXN1840 Shows Promising Action Against Copper Metabolism Disorder

阿斯利康的ALXN1840顯示出治療銅代謝紊亂的良好效果
Benzinga Real-time News ·  2022/06/23 12:14
  • AstraZeneca Plc (NASDAQ:AZN) announced detailed results from the positive FoCus Phase 3 trial of ALXN1840 in Wilson's disease, an inherited condition in which the body's pathway for removing excess copper is compromised.
  • The data showed that ALXN1840 met its primary endpoint demonstrating three-times greater copper mobilization from tissues compared to the standard of care (SoC) arm, including in patients who had been treated previously for an average of 10 years.
  • In the trial, people taking ALXN1840 experienced rapid copper mobilization, with a response at four weeks and sustained through 48 weeks.
  • In patients who were symptomatic at baseline, there were greater improvements in neurological scores for those treated with ALXN1840 compared to SoC. However, there were no significant differences between treatment groups observed at 48 weeks.1 
  • Most trial patients had low baseline symptom scores, so there was minimal room for total score improvement. As people with Wilson's disease experience a highly varied degree of symptoms, this total score may not reflect the extent of disease severity.
  • ALXN1840 was well tolerated, and the long-term safety and efficacy of ALXN1840 are being assessed in an up to 60-month extension period.
  • Price Action: AZN shares are up 1.19% at $64.31 during the market session on the last check Thursday.
  • 阿斯利康納斯達克公司(Sequoia Capital：AZN)宣佈了ALXN1840治療肝豆狀核變性的3期陽性試驗的詳細結果，該病是一種遺傳性疾病，體內清除多餘銅的途徑受到影響。
  • 數據顯示，ALXN1840達到了其主要終點，表明與標準護理(SoC)ARM相比，ALXN1840從組織中的銅動員能力提高了三倍，包括以前接受過平均10年治療的患者。
  • 在試驗中，服用ALXN1840的患者經歷了快速的銅動員，在四周起效，並持續到48周。
  • 在基線有症狀的患者中，與SOC相比，接受ALXN1840治療的患者在神經學評分方面有更大的改善。然而，在48周時觀察到的治療組之間沒有顯著差異。
  • 大多數試驗患者的基線症狀評分較低，因此總評分改善的空間很小。由於威爾遜病患者的症狀程度千差萬別，這一總分可能不能反映疾病的嚴重程度。
  • ALXN1840耐受性良好，ALXN1840的長期安全性和有效性正在進行長達60個月的延長期評估。
  • 價格行動：週四尾盤，AZN股價上漲1.19%，至64.31美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論